← All IPOs

Himalaya Nutravedics India Ltd IPO

HNIL · SME · PharmaceuticalsListed
Read filingAllotmentStock listed on 29 September
Price band
₹100 to ₹106
Issue size
₹26.5 Cr
Issue price
₹106
Lot size
1,200 shares
Min. investment
₹2,54,400

2,400 shares

Listing return
+11.32%

Listed ₹118

  1. Opens

    22 Sep 2026

  2. Closes

    24 Sep 2026

  3. Allotment

    25 Sep 2026

  4. Listing

    29 Sep 2026

Subscription

About the company

Himalaya Nutravedics India Ltd makes, markets and distributes Ayurvedic and nutraceutical products in India, and also does contract manufacturing for other companies in the same space. Its range covers classical formulations drawn from recognised Ayurvedic texts, proprietary Ayurvedic products and nutraceutical supplements, offered as soft and hard gelatin capsules, tablets, liquid orals and medicated oils; the nutraceuticals use vitamins, minerals, herbal extracts, amino acids and other permitted ingredients. The company runs both its own brands and third-party manufacturing. Production began in September 2022 at its Cherlapally, Hyderabad (Telangana) plant. Distribution is stockist-led across several states, backed by a field sales and marketing team of roughly 56 people, including regional managers and medical representatives.

Founded2022MDMr Rohit Asawa

Objective of IPO proceeds

ParticularsEstimated amount (₹ Cr.)
Funding Working Capital Requirements13.75
Investment in Branding, Digital Marketing and Sales Expansion7.5
General corporate purposes.—

Key performance indicators (KPIs)

for the year ended March 31, 2026

  • ROE63.87%
  • ROCE36.41%
  • EBITDA Margin18.82%
  • PAT Margin17.16%
  • Return on Net Worth (RoNW)45.12%

Debt-to-equity Ratio

0.31

Net Asset Value (NAV) per Equity Share

26.7

Price to Book Value

3.97

EPS (Pre IPO)

11.72

View table
KPIValue (for the year ended March 31, 2026)
ROE (%)63.87
ROCE (%)36.41
EBITDA Margin (%)18.82
PAT Margin (%)17.16
Debt-to-equity Ratio0.31
Return on Net Worth (RoNW) (%)45.12
Net Asset Value (NAV) per Equity Share (₹)26.7
Price to Book Value3.97
EPS (Pre IPO) (₹)11.72

Financials

₹ crore

Revenue

43.07

+105.1%

Total Assets

24.42

+125.7%

Profit

7.39

+231.4%
View table
Line202420252026
Revenue14.422143.07
Total Assets6.0910.8224.42
Profit0.432.237.39

Book running lead managers & registrar

Book running lead managersNirbhay Capital Services Private Limited
Registrar to the issueKFin Technologies Limited
Market maker to the issueAllwin Securities Limited

Himalaya Nutravedics India IPO contact details

Company nameHimalaya Nutravedics India
Registered officePlot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Hindustan Cables Ltd, Uppal, Hyderabad – 500051, Telangana, India.
Phone+91-9063498493
Emailinfo@himalayanutravedics.com
Websitewww.himalayanutravedics.com

Himalaya Nutravedics India IPO registrar contact details

Company nameKFin Technologies Limited
Phone+91 40671 62222 / 1800 3094001
Emailhimalaya.ipo@kfintech.com
Websitewww.kfintech.com/

Thesis

  • 1

    One integrated plant lets the company turn out medicated oils, soft and hard gelatin capsules, tablets and liquid orals, so it can cover many dosage forms for both its Ayurvedic and nutraceutical lines.

  • 2

    Its own-brand portfolio spans classical and proprietary Ayurvedic formulations plus nutraceutical supplements, addressing areas such as gut health, cardiac and metabolic wellness, diabetes, pain, immunity, infertility and general wellness.

  • 3

    The business combines its own brands with contract manufacturing for other Ayurvedic and nutraceutical firms, giving it two revenue routes.

  • 4

    In FY26 the own-brand segment brought in about Rs 22.02 crore, or 51.14% of total revenue.

  • 5

    Revenue from operations has climbed each year, from Rs 14.42 crore in FY24 to Rs 21.00 crore in FY25 and Rs 43.07 crore in FY26, while PAT rose from Rs 0.43 crore to Rs 2.23 crore and then Rs 7.39 crore.

  • 6

    Since starting production in September 2022, it has spread across several states with a stockist-based distribution network and a field sales and marketing team.

  • 7

    Management says practitioners have repeated prescriptions and re-orders, with the company relying on scientific detailing, continuing medical education, medical camps and practitioner engagement instead of mass media advertising.

Application details

  • Individual investor

    ₹100 - ₹106 · from ₹2,00,000 onwards.

    1,200sharesMin 2,400

Figures come from the company filing. This is not a recommendation.